(Q35540915)

8 August 2017

1 reference

title

Neuroprotection in PD--a role for dopamine agonists? (English)

1 reference

8 August 2017

Neuroprotection in PD—A role for dopamine agonists? (English)

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

13 March 2024

1

A. H V. Schapira

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14504378

13 March 2024

author name string

Schapira AH

1

1 reference

8 August 2017

language of work or name

English

0 references

publication date

1 September 2003

1 reference

8 August 2017

23 September 2003

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14504378

full work available at URL

13 March 2024

https://www.neurology.org/doi/full/10.1212/WNL.61.6_suppl_3.S34

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

13 March 2024

1 reference

8 August 2017

volume

61

1 reference

8 August 2017

issue

6 Suppl 3

1 reference

8 August 2017

page(s)

S34-42

1 reference

Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline

8 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Genetic and environmental factors in the cause of Parkinson's disease

13 March 2024

3

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Dopaminergic function in familial Parkinson's disease: A clinical and18F-dopa positron emission tomography study

13 March 2024

4

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

A large kindred with autosomal dominant Parkinson's disease

13 March 2024

6

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Mapping of a gene for Parkinson's disease to chromosome 4q21-q23

13 March 2024

7

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Mutation in the alpha-synuclein gene identified in families with Parkinson's disease

13 March 2024

8

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease

13 March 2024

9

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Failure to find the alpha-synuclein gene missense mutation (G209A) in 100 patients with younger onset Parkinson's disease

13 March 2024

10

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Mutation, sequence analysis, and association studies of alpha-synuclein in Parkinson's disease

13 March 2024

11

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

13 March 2024

Q64900479

12

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

The role of the alpha-synuclein gene mutation in patients with sporadic Parkinson's disease in the United Kingdom

13 March 2024

13

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system

13 March 2024

14

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system

13 March 2024

15

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Alpha-synuclein in Lewy bodies

13 March 2024

16

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha -synuclein in human and transgenic mouse brain

13 March 2024

17

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease.

13 March 2024

18

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity

13 March 2024

19

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

A Drosophila model of Parkinson's disease

13 March 2024

20

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism

13 March 2024

23

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase

13 March 2024

24

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin

13 March 2024

25

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1

13 March 2024

26

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q.

13 March 2024

27

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Lewy bodies and parkinsonism in families with parkin mutations

13 March 2024

28

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Association between early-onset Parkinson's disease and mutations in the parkin gene

13 March 2024

30

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism

13 March 2024

31

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Mutations in NR4A2 associated with familial Parkinson disease

13 March 2024

32

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Environmental risk factors in Parkinson's disease

13 March 2024

33

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case-control study in Germany.

13 March 2024

34

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

The role of environmental toxins in the etiology of Parkinson's disease

13 March 2024

35

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis

13 March 2024

36

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds

13 March 2024

37

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Chronic systemic pesticide exposure reproduces features of Parkinson's disease

13 March 2024

39

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Biochemical abnormalities and excitotoxicity in Huntington's disease brain.

13 March 2024

40

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Abnormalities of the electron transport chain in idiopathic Parkinson's disease

13 March 2024

41

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Platelet mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson Disease Research Group

13 March 2024

42

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease

13 March 2024

43

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Respiratory chain abnormalities in skeletal muscle from patients with Parkinson's disease.

13 March 2024

44

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease

13 March 2024

45

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Origin and functional consequences of the complex I defect in Parkinson's disease

13 March 2024

46

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Selective Increase of Iron in Substantia Nigra Zona Compacta of Parkinsonian Brains

13 March 2024

48

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Complex I, iron, and ferritin in Parkinson's disease substantia nigra

13 March 2024

49

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

13 March 2024

52

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

13 March 2024

53

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group.

13 March 2024

54

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Pramipexole, a dopamine D2 autoreceptor agonist, decreases the extracellular concentration of dopamine in vivo

13 March 2024

55

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro

13 March 2024

57

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Dopamine D2 receptor agonists protect against ischaemia-induced hippocampal neurodegeneration in global cerebral ischaemia.

13 March 2024

58

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Bromocriptine protects against delayed neuronal death of hippocampal neurons following cerebral ischemia in the gerbil

13 March 2024

59

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons.

13 March 2024

60

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction.

13 March 2024

61

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice.

13 March 2024

62

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Bromocriptine scavenges methamphetamine-induced hydroxyl radicals and attenuates dopamine depletion in mouse striatum

13 March 2024

63

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Reduction of lipid peroxidation in different rat brain areas after cabergoline treatment

13 March 2024

64

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

The dopamine agonist cabergoline provides neuroprotection by activation of the glutathione system and scavenging free radicals

13 March 2024

65

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Scavenging effects of dopamine agonists on nitric oxide radicals.

13 March 2024

66

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Pergolide scavenges both hydroxyl and nitric oxide free radicals in vitro and inhibits lipid peroxidation in different regions of the rat brain.

13 March 2024

67

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

The effect of pergolide and MDL 72974 on rat brain CuZn superoxide dismutase

13 March 2024

69

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Are dopamine receptor agonists neuroprotective in Parkinson's disease?

13 March 2024

70

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Dopamine D2-type agonists protect mesencephalic neurons from glutamate neurotoxicity: mechanisms of neuroprotective treatment against oxidative stress.

13 March 2024

71

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole

13 March 2024

72

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Bromocriptine protects dopaminergic neurons from levodopa-induced toxicity by stimulating D(2)receptors

13 March 2024

73

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist

13 March 2024

74

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6-hydroxydopamine

13 March 2024

75

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Neuroprotective effects of the dopamine agonists pramipexole and bromocriptine in 3-acetylpyridine-treated rats.

13 March 2024

77

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression

13 March 2024

79

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

Neuroprotective effect of riluzole in a primate model of Parkinson's disease: behavioral and histological evidence

13 March 2024

81

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S34

13 March 2024

Identifiers

1 reference

8 August 2017

1 reference